Study on plasma CC chemokine ligand 2 level and its promoter region 2518A/G polymorphism in MS patients | Zendy

Zenghui Fu | Zendy; Yan Jiang | Zendy; Jing Liu | Zendy; Zaihong Lin | Zendy; Yan Jin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Study on plasma CC chemokine ligand 2 level and its promoter region 2518A/G polymorphism in MS patients

Author(s) -

Zenghui Fu,

Yan Jiang,

Jing Liu,

Zaihong Lin,

Yan Jin

Publication year - 2020

Publication title -

european journal of inflammation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.219

H-Index - 20

eISSN - 2058-7392

pISSN - 1721-727X

DOI - 10.1177/2058739220959913

Subject(s) - pathogenesis , genotype , ccl2 , chemokine , allele , immunology , multiple sclerosis , allele frequency , peripheral blood mononuclear cell , gene , biology , medicine , inflammation , genetics , in vitro

The increase of CC chemokine ligand 2 (CCL2) is associated with multiple sclerosis (MS), but the relationship between gene promoter region 2518A/G and the pathogenesis of MS is still not obvious. Collected 54 cases of relapsing-remitting MS patients and 54 healthy controls. By detecting the CCL2-2518A/G polymorphism of MS patients and analyzing the plasma CCL2 level. High levels of A/A genotype and A allele frequency in serum CCL2 and PBMC were found in MS patients. The serum CCL2 of MS patients with A/A genotype is higher than other genotypes. Lipopolysaccharide stimulated PBMC, CCL2 levels in the supernatant of all genotypes were higher, and the A/A genotype levels of MS patients were the highest. Finally, CCL2-2518A/G polymorphism is related to the pathogenesis of MS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research